Alpelisib en post CDK 4/6 : signal d’efficacité chez les patientes RH+ mutées PI3KCA en association au fulvestrant
Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, [...]